Modulation of alcohol and nicotine responses through the endogenous opioid system

Progress in Neurobiology

Volumn 90, Issue 1, 2010, Pages 1-15

  Drews, Eva ^a   Zimmer, Andreas ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Addiction; Expression; Knockout mice; Opioid peptides; Pharmacotherapy; Reinforcement

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ALCOHOL; BETA ENDORPHIN; BREMAZOCINE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DELTA OPIATE RECEPTOR; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; DYNORPHIN; ENADOLINE; ENKEPHALIN; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; KAPPA OPIATE RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NALMEFENE; NALOXONE; NALTREXONE; NALTRIBEN; NICOTINE; NORBINALTORPHIMINE; OPIATE PEPTIDE; OPIATE RECEPTOR; PREPRODYNORPHIN; PREPROENKEPHALIN; PROOPIOMELANOCORTIN; TIFLUADOM; U 50 488; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; ALCOHOL CONSUMPTION; ALCOHOLISM; CHRONIC DRUG ADMINISTRATION; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SELF ADMINISTRATION; ENZYME RELEASE; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; HUMAN; LONG TERM EXPOSURE; LOW DRUG DOSE; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REINFORCEMENT; REVIEW; SIGNAL TRANSDUCTION; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ADAPTATION, PHYSIOLOGICAL; ALCOHOLISM; ANIMALS; AUTONOMIC AGENTS; BRAIN CHEMISTRY; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CENTRAL NERVOUS SYSTEM STIMULANTS; ETHANOL; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; NEURONS; NICOTINE; PROTEIN ISOFORMS; RECEPTORS, OPIOID; SYNAPTIC TRANSMISSION; TOBACCO USE DISORDER;

EID: 72049105137     PISSN: 03010082     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2009.09.004     Document Type: Review

References (199)

1. Akil H., Watson S.J., Young E., Lewis M.E., Khachaturian H., and Walker J.M. Endogenous opioids: biology and function. Annu. Rev. Neurosci. 7 (1984) 223-255
2. Anagnostaras S.G., and Robinson T.E. Sensitization to the psychomotor stimulant effects of amphetamine: modulation by associative learning. Behav Neurosci 110 (1996) 1397-1414
3. Altshuler H.L., Phillips P.E., and Feinhandler D.A. Alteration of ethanol self-administration by naltrexone. Life Sci. 26 (1980) 679-688
4. Araki H., Kawakami K.Y., Jin C., Suemaru K., Kitamura Y., Nagata M., Futagami K., Shibata K., Kawasaki H., and Gomita Y. Nicotine attenuates place aversion induced by naloxone in single-dose, morphine-treated rats. Psychopharmacology (Berl.) 171 (2004) 398-404
5. Arias A., Feinn R., and Kranzler H.R. Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend. 83 (2006) 262-268
6. Banks W.A., Wolf K.M., and Niehoff M.L. Effects of chronic ethanol on brain and serum level of methionine enkephalin. Peptides 24 (2003) 1935-1940
7. Bennett B., Downing C., Parker C., and Johnson T.E. Mouse genetic models in alcohol research. Trends Genet 22 (2006) 367-374
8. Bergen A.W., Kokoszka J., Peterson R., Long J.C., Virkkunen M., Linnoila M., and Goldman D. Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol. Psychiatry 2 (1997) 490-494
9. Berrendero F., Kieffer B.L., and Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J. Neurosci. 22 (2002) 10935-10940
10. Biala G., and Budzynska B. Reinstatement of nicotine-conditioned place preference by drug priming: effects of calcium channel antagonists. Eur. J. Pharmacol. 537 (2006) 85-93
11. Biala G., Budzynska B., and Kruk M. Naloxone precipitates nicotine abstinence syndrome and attenuates nicotine-induced antinociception in mice. Pharmacol. Rep. 57 (2005) 755-760
12. Blednov Y.A., Walker D., Martinez M., and Harris R.A. Reduced alcohol consumption in mice lacking preprodynorphin. Alcohol 40 (2006) 73-86
13. Bommer M., and Herz A. Neuropeptides and other secretagogues in bovine chromaffin cells: their effect on opioid peptide metabolism. Neuropeptides 13 (1989) 243-251
14. Bond C., LaForge K.S., Tian M., Melia D., Zhang S., Borg L., Gong J., Schluger J., Strong J.A., Leal S.M., Tischfield J.A., Kreek M.J., and Yu L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 9608-9613
15. Boyadjieva N., Reddy B.V., and Sarkar D.K. Forskolin delays the ethanol-induced desensitization of hypothalamic beta-endorphin neurons in primary cultures. Alcohol. Clin. Exp. Res. 21 (1997) 477-482
16. Brauer L.H., Behm F.M., Westman E.C., Patel P., and Rose J.E. Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology (Berl.) 143 (1999) 339-346
17. Byars J.A., Frost-Pineda K., Jacobs W.S., and Gold M.S. Naltrexone augments the effects of nicotine replacement therapy in female smokers. J. Addict. Dis. 24 (2005) 49-60
18. Cami J., and Farre M. Drug addiction. N Engl J Med 349 (2003) 975-986
19. Chan R.J., McBride A.W., Thomasson H.R., Ykenney A., and Crabb D.W. Allele frequencies of the preproenkephalin A (PENK) gene CA repeat in Asians, African-Americans, and Caucasians: lack of evidence for different allele frequencies in alcoholics. Alcohol. Clin. Exp. Res. 18 (1994) 533-535
20. Chong R.Y., Oswald L., Yang X., Uhart M., Lin P.I., and Wand G.S. The Micro-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology 31 (2006) 204-211
21. Ciccocioppo R., Martin-Fardon R., and Weiss F. Effect of selective blockade of mu(1) or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacology 27 (2002) 391-399
22. Clarke J.G., Stein M.D., McGarry K.A., and Gogineni A. Interest in smoking cessation among injection drug users. Am. J. Addict. 10 (2001) 159-166
23. Clarke S., Zimmer A., Zimmer A.M., Hill R.G., and Kitchen I. Region selective up-regulation of micro-, delta- and kappa-opioid receptors but not opioid receptor-like 1 receptors in the brains of enkephalin and dynorphin knockout mice. Neuroscience 122 (2003) 479-489
24. Contet C., Kieffer B.L., and Befort K. Mu opioid receptor: a gateway to drug addiction. Curr. Opin. Neurobiol. 14 (2004) 370-378
25. Corrigall W.A., Coen K.M., Adamson K.L., Chow B.L., and Zhang J. Response of nicotine self-administration in the rat to manipulations of mu-opioid and gamma-aminobutyric acid receptors in the ventral tegmental area. Psychopharmacology (Berl.) 149 (2000) 107-114
26. Cowen M.S., and Lawrence A.J. Alterations in central preproenkephalin mRNA expression after chronic free-choice ethanol consumption by fawn-hooded rats. Alcohol. Clin. Exp. Res. 25 (2001) 1126-1133
27. de Waele J.P., Kiianmaa K., and Gianoulakis C. Spontaneous and ethanol-stimulated in vitro release of beta-endorphin by the hypothalamus of AA and ANA rats. Alcohol. Clin. Exp. Res. 18 (1994) 1468-1473
28. De Waele J.P., Papachristou D.N., and Gianoulakis C. The alcohol-preferring C57BL/6 mice present an enhanced sensitivity of the hypothalamic beta-endorphin system to ethanol than the alcohol-avoiding DBA/2 mice. J. Pharmacol. Exp. Ther. 261 (1992) 788-794
29. de Wit H., and Stewart J. Reinstatement of cocaine-reinforced responding in the rat. Psychopharmacology (Berl) 75 (1981) 134-143
30. DeNoble V.J., and Mele P.C. Intravenous nicotine self-administration in rats: effects of mecamylamine, hexamethonium and naloxone. Psychopharmacology (Berl.) 184 (2006) 266-272
31. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 5274-5278
32. Di Chiara G., and Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J. Pharmacol. Exp. Ther. 244 (1988) 1067-1080
33. Drews E., Schneider M., and Koch M. Effects of the cannabinoid receptor agonist win 55,212-2 on operant behavior and locomotor activity in rats. Pharmacol. Biochem. Behav. 80 (2005) 145-150
34. Eiden L.E., Giraud P., Dave J.R., Hotchkiss A.J., and Affolter H.U. Nicotinic receptor stimulation activates enkephalin release and biosynthesis in adrenal chromaffin cells. Nature 312 (1984) 661-663
35. Evans C.J. Secrets of the opium poppy revealed. Neuropharmacology 47 Suppl. 1 (2004) 293-299
36. Evans C.J., Keith Jr. D.E., Morrison H., Magendzo K., and Edwards R.H. Cloning of a delta opioid receptor by functional expression. Science 258 (1992) 1952-1955
37. Everitt B.J., and Robbins T.W. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat. Neurosci. 8 (2005) 1481-1489
38. Fadda P., Tronci S., Colombo G., and Fratta W. Differences in the opioid system in selected brain regions of alcohol-preferring and alcohol-nonpreferring rats. Alcohol. Clin. Exp. Res. 23 (1999) 1296-1305
39. Feltenstein M.W., and See R.E. The neurocircuitry of addiction: an overview. Br. J. Pharmacol. 154 (2008) 261-274
40. Filliol D., Ghozland S., Chluba J., Martin M., Matthes H.W., Simonin F., Befort K., Gaveriaux-Ruff C., Dierich A., LeMeur M., Valverde O., Maldonado R., and Kieffer B.L. Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat. Genet. 25 (2000) 195-200
41. France C.P., and Woods J.H. Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. J Pharmacol Exp Ther 250 (1989) 937-943
42. Franke P., Nothen M.M., Wang T., Neidt H., Knapp M., Lichtermann D., Weiffenbach O., Mayer P., Hollt V., Propping P., and Maier W. Human delta-opioid receptor gene and susceptibility to heroin and alcohol dependence. Am. J. Med. Genet. 88 (1999) 462-464
43. Froehlich J.C., Harts J., Lumeng L., and Li T.K. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol. Biochem. Behav. 35 (1990) 385-390
44. Galeote L., Berrendero F., Andreea Bura S., Zimmer A., and Maldonado R. Prodynorphin gene disruption increases the sensitivity to nicotine self-administration in mice. Int. J. Neuropsychopharmacol. (2008) 1-11
45. Galeote L., Kieffer B.L., Maldonado R., and Berrendero F. Mu-opioid receptors are involved in the tolerance to nicotine antinociception. J. Neurochem. 97 (2006) 416-423
46. Galeote L., Maldonado R., and Berrendero F. Involvement of kappa/dynorphin system in the development of tolerance to nicotine-induced antinociception. J. Neurochem. 105 (2008) 1358-1368
47. Gelernter J., Kranzler H., and Cubells J. Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol. Psychiatry 4 (1999) 476-483
48. Gellert V.F., and Sparber S.B. A comparison of the effects of naloxone upon body weight loss and suppression of fixed-ratio operant behavior in morphine-dependent rats. J Pharmacol Exp Ther 201 (1977) 44-54
49. Ghozland S., Chu K., Kieffer B.L., and Roberts A.J. Lack of stimulant and anxiolytic-like effects of ethanol and accelerated development of ethanol dependence in mu-opioid receptor knockout mice. Neuropharmacology 49 (2005) 493-501
50. Gianoulakis C. Characterization of the effects of acute ethanol administration on the release of beta-endorphin peptides by the rat hypothalamus. Eur. J. Pharmacol. 180 (1990) 21-29
51. Gianoulakis C. Influence of the endogenous opioid system on high alcohol consumption and genetic predisposition to alcoholism. J. Psychiatry Neurosci. 26 (2001) 304-318
52. Gianoulakis C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr. Top. Med. Chem. 4 (2004) 39-50
53. Gianoulakis C., Hutchison W.D., and Kalant H. Effects of ethanol treatment and withdrawal on biosynthesis and processing of proopiomelanocortin by the rat neurointermediate lobe. Endocrinology 122 (1988) 817-825
54. Gorelick D.A., Rose J., and Jarvik M.E. Effect of naloxone on cigarette smoking. J. Subst. Abuse 1 (1988) 153-159
55. Grahame N.J., Mosemiller A.K., Low M.J., and Froehlich J.C. Naltrexone and alcohol drinking in mice lacking beta-endorphin by site-directed mutagenesis. Pharmacol. Biochem. Behav. 67 (2000) 759-766
56. Grant B.F., Hasin D.S., Chou S.P., Stinson F.S., and Dawson D.A. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch. Gen. Psychiatry 61 (2004) 1107-1115
57. Grisel J.E., Mogil J.S., Grahame N.J., Rubinstein M., Belknap J.K., Crabbe J.C., and Low M.J. Ethanol oral self-administration is increased in mutant mice with decreased beta-endorphin expression. Brain Res. 835 (1999) 62-67
58. Guitart-Masip M., Gimenez-Llort L., Fernandez-Teruel A., Canete T., Tobena A., Ogren S.O., Terenius L., and Johansson B. Reduced ethanol response in the alcohol-preferring RHA rats and neuropeptide mRNAs in relevant structures. Eur. J. Neurosci. 23 (2006) 531-540
59. Gulya K., Orpana A.K., Sikela J.M., and Hoffman P.L. Prodynorphin and vasopressin mRNA levels are differentially affected by chronic ethanol ingestion in the mouse. Brain Res. Mol. Brain Res. 20 (1993) 1-8
60. Hahn B., Stolerman I.P., and Shoaib M. Kappa-opioid receptor modulation of nicotine-induced behaviour. Neuropharmacology 39 (2000) 2848-2855
61. Hall F.S., Sora I., and Uhl G.R. Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology (Berl.) 154 (2001) 43-49
62. Hayward M.D., Hansen S.T., Pintar J.E., and Low M.J. Operant self-administration of ethanol in C57BL/6 mice lacking beta-endorphin and enkephalin. Pharmacol. Biochem. Behav. 79 (2004) 171-181
63. Hollt V., and Horn G. Effect of nicotine on mRNA levels encoding opioid peptides, vasopressin and alpha 3 nicotinic receptor subunit in the rat. Clin. Investig. 70 (1992) 224-231
64. Holter S.M., Henniger M.S., Lipkowski A.W., and Spanagel R. Kappa-opioid receptors and relapse-like drinking in long-term ethanol-experienced rats. Psychopharmacology (Berl.) 153 (2000) 93-102
65. Houdi A.A., Dasgupta R., and Kindy M.S. Effect of nicotine use and withdrawal on brain preproenkephalin A mRNA. Brain Res. 799 (1998) 257-263
66. Houdi A.A., Pierzchala K., Marson L., Palkovits M., and Van Loon G.R. Nicotine-induced alteration in Tyr-Gly-Gly and Met-enkephalin in discrete brain nuclei reflects altered enkephalin neuron activity. Peptides 12 (1991) 161-166
67. Hutchison K.E., Monti P.M., Rohsenow D.J., Swift R.M., Colby S.M., Gnys M., Niaura R.S., and Sirota A.D. Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology (Berl.) 142 (1999) 139-143
68. Hyytia P. Involvement of mu-opioid receptors in alcohol drinking by alcohol-preferring AA rats. Pharmacol. Biochem. Behav. 45 (1993) 697-701
69. Hyytia P., and Kiianmaa K. Suppression of ethanol responding by centrally administered CTOP and naltrindole in AA and Wistar rats. Alcohol. Clin. Exp. Res. 25 (2001) 25-33
70. Ingman K., Salvadori S., Lazarus L., Korpi E.R., and Honkanen A. Selective delta-opioid receptor antagonist N,N(CH3)2-Dmt-Tic-OH does not reduce ethanol intake in alcohol-preferring AA rats. Addict. Biol. 8 (2003) 173-179
71. Ise Y., Narita M., Nagase H., and Suzuki T. Modulation of opioidergic system on mecamylamine-precipitated nicotine-withdrawal aversion in rats. Psychopharmacology (Berl.) 151 (2000) 49-54
72. Isola R., Zhang H., Tejwani G.A., Neff N.H., and Hadjiconstantinou M. Dynorphin and prodynorphin mRNA changes in the striatum during nicotine withdrawal. Synapse 62 (2008) 448-455
73. Isola R., Zhang H., Tejwani G.A., Neff N.H., and Hadjiconstantinou M. Acute nicotine changes dynorphin and prodynorphin mRNA in the striatum. Psychopharmacology (Berl.) 201 (2009) 507-516
74. Jaffe A.J., Rounsaville B., Chang G., Schottenfeld R.S., Meyer R.E., and O'Malley S.S. Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J. Consult. Clin. Psychol. 64 (1996) 1044-1053
75. June H.L., Cummings R., Eiler II W.J., Foster K.L., McKay P.F., Seyoum R., Garcia M., McCane S., Grey C., Hawkins S.E., and Mason D. Central opioid receptors differentially regulate the nalmefene-induced suppression of ethanol- and saccharin-reinforced behaviors in alcohol-preferring (P) rats. Neuropsychopharmacology 29 (2004) 285-299
76. June H.L., Grey C., Warren-Reese C., Durr L.F., Ricks-Cord A., Johnson A., McCane S., Williams L.S., Mason D., Cummings R., and Lawrence A. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats. Alcohol. Clin. Exp. Res. 22 (1998) 2174-2185
77. Kalivas P.W., and Stewart J. Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Brain Res Rev 16 (1991) 223-244
78. Kamerling S.G., Wettstein J.G., Sloan J.W., Su T.P., and Martin W.R. Interaction between nicotine and endogenous opioid mechanisms in the unanesthetized dog. Pharmacol. Biochem. Behav. 17 (1982) 733-740
79. Keith L.D., Crabbe J.C., Robertson L.M., and Kendall J.W. Ethanol-stimulated endorphin and corticotropin secretion in vitro. Brain Res. 367 (1986) 222-229
80. Kieffer B.L. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell. Mol. Neurobiol. 15 (1995) 615-635
81. Kieffer B.L., Befort K., Gaveriaux-Ruff C., and Hirth C.G. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 12048-12052
82. Kieffer B.L., and Evans C.J. Opioid receptors: from binding sites to visible molecules in vivo. Neuropharmacology 56 Suppl. 1 (2009) 205-212
83. Kieffer B.L., and Gaveriaux-Ruff C. Exploring the opioid system by gene knockout. Prog. Neurobiol. 66 (2002) 285-306
84. Kiguchi N., Maeda T., Tsuruga M., Yamamoto A., Yamamoto C., Ozaki M., and Kishioka S. Involvement of spinal Met-enkephalin in nicotine-induced antinociception in mice. Brain Res. 1189 (2008) 70-77
85. Kim S.G., Kim C.M., Choi S.W., Jae Y.M., Lee H.G., Son B.K., Kim J.G., Choi Y.S., Kim H.O., Kim S.Y., and Oslin D.W. A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl.) 201 (2009) 611-618
86. King A.C., and Meyer P.J. Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol. Biochem. Behav. 66 (2000) 563-572
87. Koenig H.N., and Olive M.F. Ethanol consumption patterns and conditioned place preference in mice lacking preproenkephalin. Neurosci. Lett. 325 (2002) 75-78
88. Koob G.F., Roberts A.J., Schulteis G., Parsons L.H., Heyser C.J., Hyytia P., Merlo-Pich E., and Weiss F. Neurocircuitry targets in ethanol reward and dependence. Alcohol. Clin. Exp. Res. 22 (1998) 3-9
89. Kovacs K.M., Szakall I., O'Brien D., Wang R., Vinod K.Y., Saito M., Simonin F., Kieffer B.L., and Vadasz C. Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice. Alcohol. Clin. Exp. Res. 29 (2005) 730-738
90. Kreek M.J., LaForge K.S., and Butelman E. Pharmacotherapy of addictions. Nat. Rev. Drug Discov. 1 (2002) 710-726
91. Krishnan-Sarin S., Jing S.L., Kurtz D.L., Zweifel M., Portoghese P.S., Li T.K., and Froehlich J.C. The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology (Berl.) 120 (1995) 177-185
92. Krishnan-Sarin S., Meandzija B., and O'Malley S. Naltrexone and nicotine patch smoking cessation: a preliminary study. Nicotine Tob. Res. 5 (2003) 851-857
93. Krishnan-Sarin S., Portoghese P.S., Li T.K., and Froehlich J.C. The delta 2-opioid receptor antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference. Pharmacol. Biochem. Behav. 52 (1995) 153-159
94. Krishnan-Sarin S., Rosen M.I., and O'Malley S.S. Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Arch. Gen. Psychiatry 56 (1999) 663-668
95. LaBuda C.J., and Fuchs P.N. The anxiolytic effect of acute ethanol or diazepam exposure is unaltered in mu-opioid receptor knockout mice. Brain Res. Bull. 55 (2001) 755-760
96. Le Foll B., Diaz J., and Sokoloff P. Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. Synapse 47 (2003) 176-183
97. Lerman C., Wileyto E.P., Patterson F., Rukstalis M., Audrain-McGovern J., Restine S., Shields P.G., Kaufmann V., Redden D., Benowitz N., and Berrettini W.H. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J. 4 (2004) 184-192
98. Li X.W., Li T.K., and Froehlich J.C. Enhanced sensitivity of the nucleus accumbens proenkephalin system to alcohol in rats selectively bred for alcohol preference. Brain Res. 794 (1998) 35-47
99. Lindholm S., Ploj K., Franck J., and Nylander I. Repeated ethanol administration induces short- and long-term changes in enkephalin and dynorphin tissue concentrations in rat brain. Alcohol 22 (2000) 165-171
100. Lindholm S., Werme M., Brene S., and Franck J. The selective kappa-opioid receptor agonist U50,488H attenuates voluntary ethanol intake in the rat. Behav. Brain Res. 120 (2001) 137-146
101. Littleton J., Barron S., Prendergast M., and Nixon S.J. Smoking kills (alcoholics)! shouldn't we do something about it?. Alcohol Alcohol. 42 (2007) 167-173
102. Liu X., Palmatier M.I., Caggiula A.R., Sved A.F., Donny E.C., Gharib M., and Booth S. Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats. Psychopharmacology (Berl.) 202 (2009) 589-598
103. Livett B.G., Dean D.M., Whelan L.G., Udenfriend S., and Rossier J. Co-release of enkephalin and catecholamines from cultured adrenal chromaffin cells. Nature 289 (1981) 317-319
104. Loh el W., Fann C.S., Chang Y.T., Chang C.J., and Cheng A.T. Endogenous opioid receptor genes and alcohol dependence among Taiwanese Han. Alcohol. Clin. Exp. Res. 28 (2004) 15-19
105. Lowery E.G., Sparrow A.M., Breese G.R., Knapp D.J., and Thiele T.E. The CRF-1 receptor antagonist, CP-154,526, attenuates stress-induced increases in ethanol consumption by BALB/cJ mice. Alcohol. Clin. Exp. Res. 32 (2008) 240-248
106. MacArthur L., Iacangelo A.L., Hsu C.M., and Eiden L.E. Enkephalin biosynthesis is coupled to secretory activity via transcription of the proenkephalin A gene. J. Physiol. Paris 86 (1992) 89-98
107. Malin D.H., Lake J.R., Carter V.A., Cunningham J.S., and Wilson O.B. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl.) 112 (1993) 339-342
108. Marco E.M., Granstrem O., Moreno E., Llorente R., Adriani W., Laviola G., and Viveros M.P. Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB1 and mu-opioid receptors in rats. Eur. J. Pharmacol. 557 (2007) 37-43
109. Margioris A.N., Markogiannakis E., Makrigiannakis A., and Gravanis A. PC12 rat pheochromocytoma cells synthesize dynorphin. Its secretion is modulated by nicotine and nerve growth factor. Endocrinology 131 (1992) 703-709
110. Margolis E.B., Fields H.L., Hjelmstad G.O., and Mitchell J.M. Delta-opioid receptor expression in the ventral tegmental area protects against elevated alcohol consumption. J. Neurosci. 28 (2008) 12672-12681
111. Marinelli P.W., Kiianmaa K., and Gianoulakis C. Opioid propeptide mRNA content and receptor density in the brains of AA and ANA rats. Life Sci. 66 (2000) 1915-1927
112. Maskos U., Molles B.E., Pons S., Besson M., Guiard B.P., Guilloux J.P., Evrard A., Cazala P., Cormier A., Mameli-Engvall M., Dufour N., Cloez-Tayarani I., Bemelmans A.P., Mallet J., Gardier A.M., David V., Faure P., Granon S., and Changeux J.P. Nicotine reinforcement and cognition restored by targeted expression of nicotinic receptors. Nature 436 (2005) 103-107
113. Mathieu A.M., Caboche J., and Besson M.J. Distribution of preproenkephalin, preprotachykinin A, and preprodynorphin mRNAs in the rat nucleus accumbens: effect of repeated administration of nicotine. Synapse 23 (1996) 94-106
114. Mathieu-Kia A.M., and Besson M.J. Repeated administration of cocaine, nicotine and ethanol: effects on preprodynorphin, preprotachykinin A and preproenkephalin mRNA expression in the dorsal and the ventral striatum of the rat. Brain Res. Mol. Brain Res. 54 (1998) 141-151
115. Mendez M., Morales-Mulia M., and Perez-Luna J.M. Ethanol-induced changes in proenkephalin mRNA expression in the rat nigrostriatal pathway. J. Mol. Neurosci. 34 (2008) 225-234
116. Minami M., and Satoh M. Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci. Res. 23 (1995) 121-145
117. Motoshima S., Suemaru K., Kawasaki Y., Jin C., Kawasaki H., Gomita Y., and Araki H. Effects of alpha4beta2 and alpha7 nicotinic acetylcholine receptor antagonists on place aversion induced by naloxone in single-dose morphine-treated rats. Eur. J. Pharmacol. 519 (2005) 91-95
118. Munafo M.R., Elliot K.M., Murphy M.F., Walton R.T., and Johnstone E.C. Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics J. 7 (2007) 353-361
119. Myers R.D., Borg S., and Mossberg R. Antagonism by naltrexone of voluntary alcohol selection in the chronically drinking macaque monkey. Alcohol 3 (1986) 383-388
120. Nylander I., Hyytia P., Forsander O., and Terenius L. Differences between alcohol-preferring (AA) and alcohol-avoiding (ANA) rats in the prodynorphin and proenkephalin systems. Alcohol. Clin. Exp. Res. 18 (1994) 1272-1279
121. O'Malley S.S. Opioid antagonists in the treatment of alcohol dependence: clinical efficacy and prevention of relapse. Alcohol Alcohol. Suppl. 1 (1996) 77-81
122. O'Malley S.S., Krishnan-Sarin S., Farren C., Sinha R., and Kreek M.J. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl.) 160 (2002) 19-29
123. Oswald L.M., and Wand G.S. Opioids and alcoholism. Physiol. Behav. 81 (2004) 339-358
124. Ploj K., Roman E., Gustavsson L., and Nylander I. Basal levels and alcohol-induced changes in nociceptin/orphanin FQ, dynorphin, and enkephalin levels in C57BL/6J mice. Brain Res. Bull. 53 (2000) 219-226
125. Pratt W.M., and Davidson D. Role of the HPA axis and the A118G polymorphism of the {micro}-opioid receptor in stress-induced drinking behavior. Alcohol Alcohol. (2009)
126. Przewlocka B., Turchan J., Lason W., and Przewlocki R. Ethanol withdrawal enhances the prodynorphin system activity in the rat nucleus accumbens. Neurosci. Lett. 238 (1997) 13-16
127. Racz I., Schurmann B., Karpushova A., Reuter M., Cichon S., Montag C., Furst R., Schutz C., Franke P.E., Strohmaier J., Wienker T.F., Terenius L., Osby U., Gunnar A., Maier W., Bilkei-Gorzo A., Nothen M., and Zimmer A. The opioid peptides enkephalin and beta-endorphin in alcohol dependence. Biol. Psychiatry (2008)
128. Rasmussen D.D., Bryant C.A., Boldt B.M., Colasurdo E.A., Levin N., and Wilkinson C.W. Acute alcohol effects on opiomelanocortinergic regulation. Alcohol. Clin. Exp. Res. 22 (1998) 789-801
129. Ray R., Jepson C., Patterson F., Strasser A., Rukstalis M., Perkins K., Lynch K.G., O'Malley S., Berrettini W.H., and Lerman C. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl.) 188 (2006) 355-363
130. Ray R., Jepson C., Wileyto P., Patterson F., Strasser A.A., Rukstalis M., Perkins K., Blendy J., and Lerman C. CREB1 haplotypes and the relative reinforcing value of nicotine. Mol. Psychiatry 12 (2007) 615-617
131. Rezayof A., Nazari-Serenjeh F., Zarrindast M.R., Sepehri H., and Delphi L. Morphine-induced place preference: involvement of cholinergic receptors of the ventral tegmental area. Eur. J. Pharmacol. 562 (2007) 92-102
132. Rezayof A., Zatali H., Haeri-Rohani A., and Zarrindast M.R. Dorsal hippocampal muscarinic and nicotinic receptors are involved in mediating morphine reward. Behav. Brain Res. 166 (2006) 281-290
133. Riala K., Hakko H., Isohanni M., Jarvelin M.R., and Rasanen P. Teenage smoking and substance use as predictors of severe alcohol problems in late adolescence and in young adulthood. J. Adolesc. Health 35 (2004) 245-254
134. Roberts A.J., Gold L.H., Polis I., McDonald J.S., Filliol D., Kieffer B.L., and Koob G.F. Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol. Clin. Exp. Res. 25 (2001) 1249-1256
135. Roberts A.J., McDonald J.S., Heyser C.J., Kieffer B.L., Matthes H.W., Koob G.F., and Gold L.H. mu-Opioid receptor knockout mice do not self-administer alcohol. J. Pharmacol. Exp. Ther. 293 (2000) 1002-1008
136. Robinson T.E., and Berridge K.C. The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95 Suppl 2 (2000) S91-117
137. Rohsenow D.J., Monti P.M., Hutchison K.E., Swift R.M., Colby S.M., and Kaplan G.B. Naltrexone's effects on reactivity to alcohol cues among alcoholic men. J. Abnorm. Psychol. 109 (2000) 738-742
138. Rommelspacher H., Smolka M., Schmidt L.G., Samochowiec J., and Hoehe M.R. Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals. Alcohol 24 (2001) 129-135
139. Rosin A., Lindholm S., Franck J., and Georgieva J. Downregulation of kappa opioid receptor mRNA levels by chronic ethanol and repetitive cocaine in rat ventral tegmentum and nucleus accumbens. Neurosci. Lett. 275 (1999) 1-4
140. Rukstalis M., Jepson C., Strasser A., Lynch K.G., Perkins K., Patterson F., and Lerman C. Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm. Psychopharmacology (Berl.) 180 (2005) 41-48
141. Saland L.C., Hastings C.M., Abeyta A., and Chavez J.B. Chronic ethanol modulates delta and mu-opioid receptor expression in rat CNS: immunohistochemical analysis with quantitiative confocal microscopy. Neurosci. Lett. 381 (2005) 163-168
142. Sanchis-Segura C., and Spanagel R. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. Addict. Biol. 11 (2006) 2-38
143. Sandi C., Borrell J., and Guaza C. Involvement of kappa type opioids on ethanol drinking. Life Sci. 42 (1988) 1067-1075
144. Schluger J.H., Ho A., Borg L., Porter M., Maniar S., Gunduz M., Perret G., King A., and Kreek M.J. Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol. Clin. Exp. Res. 22 (1998) 1430-1436
145. Schulz R., Wuster M., Duka T., and Herz A. Acute and chronic ethanol treatment changes endorphin levels in brain and pituitary. Psychopharmacology (Berl.) 68 (1980) 221-227
146. Scott D.J., Domino E.F., Heitzeg M.M., Koeppe R.A., Ni L., Guthrie S., and Zubieta J.K. Smoking modulation of mu-opioid and dopamine D2 receptor-mediated neurotransmission in humans. Neuropsychopharmacology 32 (2007) 450-457
147. Seizinger B.R., Bovermann K., Hollt V., and Herz A. Enhanced activity of the beta-endorphinergic system in the anterior and neurointermediate lobe of the rat pituitary after chronic treatment with ethanol liquid diet. J. Pharmacol. Exp. Ther. 230 (1984) 455-461
148. Seizinger B.R., Bovermann K., Maysinger D., Hollt V., and Herz A. Differential effects of acute and chronic ethanol treatment on particular opioid peptide systems in discrete regions of rat brain and pituitary. Pharmacol. Biochem. Behav. 18 Suppl. 1 (1983) 361-369
149. Self D.W., and Nestler E.J. Molecular mechanisms of drug reinforcement and addiction. Annu Rev Neurosci 18 (1995) 463-495
150. Shippenberg T.S. The dynorphin/kappa opioid receptor system: a new target for the treatment of addiction and affective disorders?. Neuropsychopharmacology 34 (2009) 247
151. Shippenberg T.S., LeFevour A., and Chefer V.I. Targeting endogenous mu- and delta-opioid receptor systems for the treatment of drug addiction. CNS Neurol. Disord. Drug Targets 7 (2008) 442-453
152. Shippenberg T.S., Zapata A., and Chefer V.I. Dynorphin and the pathophysiology of drug addiction. Pharmacol. Ther. 116 (2007) 306-321
153. Sillaber I., Rammes G., Zimmermann S., Mahal B., Zieglgansberger W., Wurst W., Holsboer F., and Spanagel R. Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors. Science 296 (2002) 931-933
154. Singer G., Oei T.P., and Wallace M. Schedule-induced self-injection of drugs. Neurosci. Biobehav. Rev. 6 (1982) 77-83
155. Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol. Rev. 89 (2009) 649-705
156. Spanagel R., Herz A., and Shippenberg T.S. The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J. Neurochem. 55 (1990) 1734-1740
157. Spanagel R., Herz A., and Shippenberg T.S. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 2046-2050
158. Sparta D.R., Ferraro III F.M., Fee J.R., Knapp D.J., Breese G.R., and Thiele T.E. The alcohol deprivation effect in C57BL/6J mice is observed using operant self-administration procedures and is modulated by CRF-1 receptor signaling. Alcohol. Clin. Exp. Res. 33 (2009) 31-42
159. Sparta D.R., Sparrow A.M., Lowery E.G., Fee J.R., Knapp D.J., and Thiele T.E. Blockade of the corticotropin releasing factor type 1 receptor attenuates elevated ethanol drinking associated with drinking in the dark procedures. Alcohol. Clin. Exp. Res. 32 (2008) 259-265
160. Stinus L., Caille S., and Koob G.F. Opiate withdrawal-induced place aversion lasts for up to 16 weeks. Psychopharmacology (Berl) 149 (2000) 115-120
161. Suh H.W., Song D.K., Choi S.R., Chung K.M., and Kim Y.H. Nicotine enhances morphine- and beta-endorphin-induced antinociception at the supraspinal level in the mouse. Neuropeptides 30 (1996) 479-484
162. Suh H.W., Song D.K., Lee K.J., Choi S.R., and Kim Y.H. Intrathecally injected nicotine enhances the antinociception induced by morphine but not beta-endorphin, D-Pen2,5-enkephalin and U50,488H administered intrathecally in the mouse. Neuropeptides 30 (1996) 373-378
163. Sullivan M.A., and Covey L.S. Current perspectives on smoking cessation among substance abusers. Curr. Psychiatry Rep. 4 (2002) 388-396
164. Town T., Abdullah L., Crawford F., Schinka J., Ordorica P.I., Francis E., Hughes P., Duara R., and Mullan M. Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. Am. J. Med. Genet. 88 (1999) 458-461
165. Turchan J., Przewlocka B., Toth G., Lason W., Borsodi A., and Przewlocki R. The effect of repeated administration of morphine, cocaine and ethanol on mu and delta opioid receptor density in the nucleus accumbens and striatum of the rat. Neuroscience 91 (1999) 971-977
166. Tzavara E.T., Monory K., Hanoune J., and Nomikos G.G. Nicotine withdrawal syndrome: behavioural distress and selective up-regulation of the cyclic AMP pathway in the amygdala. Eur. J. Neurosci. 16 (2002) 149-153
167. Urayama A., King K., Gaskin F.S., Farr S.A., and Banks W.A. Effects of chronic ethanol administration on brain interstitial fluid levels of methionine-enkephalin as measured by microdialysis in vivo. Peptides 27 (2006) 2201-2206
168. Vadasz C., Saito M., Gyetvai B., Mikics E., and Vadasz II C. Scanning of five chromosomes for alcohol consumption loci. Alcohol 22 (2000) 25-34
169. Vengeliene V., Bilbao A., Molander A., and Spanagel R. Neuropharmacology of alcohol addiction. Br. J. Pharmacol. 154 (2008) 299-315
170. Volpicelli J.R., Alterman A.I., Hayashida M., and O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 49 (1992) 876-880
171. Walker B.M., and Koob G.F. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence. Neuropsychopharmacology 33 (2008) 643-652
172. Wand G.S., McCaul M., Yang X., Reynolds J., Gotjen D., Lee S., and Ali A. The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26 (2002) 106-114
173. Wang X., Wang G., Lemos J.R., and Treistman S.N. Ethanol directly modulates gating of a dihydropyridine-sensitive Ca2+ channel in neurohypophysial terminals. J. Neurosci. 14 (1994) 5453-5460
174. Wang Z., Ray R., Faith M., Tang K., Wileyto E.P., Detre J.A., and Lerman C. Nicotine abstinence-induced cerebral blood flow changes by genotype. Neurosci. Lett. 438 (2008) 275-280
175. Watkins S.S., Stinus L., Koob G.F., and Markou A. Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J. Pharmacol. Exp. Ther. 292 (2000) 1053-1064
176. Weiss F., Mitchiner M., Bloom F.E., and Koob G.F. Free-choice responding for ethanol versus water in alcohol preferring (P) and unselected Wistar rats is differentially modified by naloxone, bromocriptine, and methysergide. Psychopharmacology (Berl.) 101 (1990) 178-186
177. Wendel B., and Hoehe M.R. The human mu opioid receptor gene: 5′ regulatory and intronic sequences. J. Mol. Med. 76 (1998) 525-532
178. Wewers M.E., Dhatt R., and Tejwani G.A. Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology (Berl.) 140 (1998) 185-190
179. Wewers M.E., Dhatt R.K., Snively T.A., and Tejwani G.A. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkelphalin levels in rats. Brain Res. 822 (1999) 107-113
180. Wewers M.E., Tejwani G.A., and Anderson J. Plasma nicotine, plasma beta-endorphin and mood states during periods of chronic smoking, abstinence and nicotine replacement. Psychopharmacology (Berl.) 116 (1994) 98-102
181. Williams K.L., and Woods J.H. Oral ethanol-reinforced responding in rhesus monkeys: effects of opioid antagonists selective for the mu-, kappa-, or delta-receptor. Alcohol. Clin. Exp. Res. 22 (1998) 1634-1639
182. Wilson S.P. Regulation of proenkephalin synthesis in adrenal medullary chromaffin cells. J. Neurochem. 56 (1991) 945-952
183. Wilson S.P., Chang K.J., and Viveros O.H. Proportional secretion of opioid peptides and catecholamines from adrenal chromaffin cells in culture. J. Neurosci. 2 (1982) 1150-1156
184. Winkler A., Buzas B., Siems W.E., Heder G., and Cox B.M. Effect of ethanol drinking on the gene expression of opioid receptors, enkephalinase, and angiotensin-converting enzyme in two inbred mice strains. Alcohol. Clin. Exp. Res. 22 (1998) 1262-1271
185. Wise R.A. Action of drugs of abuse on brain reward systems. Pharmacol. Biochem. Behav. 13 Suppl. 1 (1980) 213-223
186. Wong G.Y., Wolter T.D., Croghan G.A., Croghan I.T., Offord K.P., and Hurt R.D. A randomized trial of naltrexone for smoking cessation. Addiction 94 (1999) 1227-1237
187. Xuei X., Dick D., Flury-Wetherill L., Tian H.J., Agrawal A., Bierut L., Goate A., Bucholz K., Schuckit M., Nurnberger Jr. J., Tischfield J., Kuperman S., Porjesz B., Begleiter H., Foroud T., and Edenberg H.J. Association of the kappa-opioid system with alcohol dependence. Mol. Psychiatry 11 (2006) 1016-1024
188. Xuei X., Flury-Wetherill L., Bierut L., Dick D., Nurnberger Jr. J., Foroud T., and Edenberg H.J. The opioid system in alcohol and drug dependence: family-based association study. Am. J. Med. Genet. B: Neuropsychiatr. Genet. (2007)
189. Yanase T., Nawata H., Kato K., and Ibayashi H. Catecholamines and opioid peptides in human phaeochromocytomas. Acta Endocrinol. (Copenh.) 113 (1986) 378-384
190. Yanase T., Nawata H., Kato K., and Ibayashi H. Preproenkephalin B-derived opioid peptides in human phaeochromocytomas. Acta Endocrinol. (Copenh.) 114 (1987) 446-451
191. Yoo J.H., Cho J.H., Lee S.Y., Loh H.H., Ho I.K., and Jang C.G. Reduced nNOS expression induced by repeated nicotine treatment in mu-opioid receptor knockout mice. Neurosci. Lett. 380 (2005) 70-74
192. Yoo J.H., Lee S.Y., Loh H.H., Ho I.K., and Jang C.G. Loss of nicotine-induced behavioral sensitization in micro-opioid receptor knockout mice. Synapse 51 (2004) 219-223
193. Zarrindast M.R., Faraji N., Rostami P., Sahraei H., and Ghoshouni H. Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice. Pharmacol. Biochem. Behav. 74 (2003) 363-369
194. Zarrindast M.R., Fattahi Z., Rostami P., and Rezayof A. Role of the cholinergic system in the rat basolateral amygdala on morphine-induced conditioned place preference. Pharmacol. Biochem. Behav. 82 (2005) 1-10
195. Zarrindast M.R., and Mohajeri S. Influence of ATP-dependent K+ channels on nicotine-induced inhibition of withdrawal in morphine-dependent mice. Eur. J. Pharmacol. 552 (2006) 90-98
196. Zhang H., Kranzler H.R., Weiss R.D., Luo X., Brady K.T., Anton R.F., Farrer L.A., and Gelernter J. Pro-opiomelanocortin gene variation related to alcohol or drug dependence: evidence and replications across family- and population-based studies. Biol. Psychiatry 66 (2009) 128-136
197. Zhang H., Kranzler H.R., Yang B.Z., Luo X., and Gelernter J. The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. Mol. Psychiatry 13 (2008) 531-543
198. Zhang L., Kendler K.S., and Chen X. The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav. Brain Funct. 2 (2006) 28
199. Zhou Y., Franck J., Spangler R., Maggos C.E., Ho A., and Kreek M.J. Reduced hypothalamic POMC and anterior pituitary CRF1 receptor mRNA levels after acute, but not chronic, daily "binge" intragastric alcohol administration. Alcohol. Clin. Exp. Res. 24 (2000) 1575-1582